MoonLake Immunotherapeutics (MLTX) Operating Income (2021 - 2026)

MoonLake Immunotherapeutics' Operating Income history runs 6 years deep, the most recent figure standing at -$70.0 million for Q1 2026.

• On a quarterly basis, Operating Income fell 47.47% year-over-year to -$70.0 million in Q1 2026; TTM through Mar 2026 was -$267.4 million, a 56.58% decrease from a year earlier, with the FY2025 full-year figure at -$244.8 million, down 71.1% from the prior year.
• Operating Income declined to -$70.0 million in Q1 2026 per MLTX's latest filing, from -$65.2 million in the prior quarter.
• Across five years, Operating Income topped out at -$12.9 million in Q1 2023 and bottomed at -$71.4 million in Q3 2025.
• The 5-year median for Operating Income is -$19.8 million (2024), against an average of -$33.9 million.
• Biggest YoY gain for Operating Income was 68.84% in 2022; the steepest drop was 16840.81% in 2022.
• Year by year, Operating Income stood at -$16.7 million in 2022, then gained by 9.99% to -$15.0 million in 2023, then plunged by 229.9% to -$49.6 million in 2024, then plunged by 31.54% to -$65.2 million in 2025, then fell by 7.37% to -$70.0 million in 2026.
• Per Business Quant, the three latest MLTX Operating Income figures stand at -$70.0 million (Q1 2026), -$65.2 million (Q4 2025), and -$71.4 million (Q3 2025).